<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127829</url>
  </required_header>
  <id_info>
    <org_study_id>D7913C00022</org_study_id>
    <nct_id>NCT00127829</nct_id>
  </id_info>
  <brief_title>Study Evaluating Gefitinib (IRESSA速) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic</brief_title>
  <acronym>AGUS</acronym>
  <official_title>A Phase I, Open-Label, Dose Escalation Study Evaluating High-Dose Gefitinib (IRESSA速) on Weekly and Twice Weekly Schedules in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study will determine the safety profile and maximum tolerated dose (MTD) of orally
      administered gefitinib on a weekly and twice weekly schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib (IRESSA速)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>1</arm_group_label>
    <other_name>IRESSA速</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed solid tumor refractory to conventional treatment or whom no
             standard of treatment exists

          -  Life expectancy of &gt; 12 weeks

          -  World Health Organization (WHO) performance status of &lt; 2

        Exclusion Criteria:

          -  Known severe hypersensitivity to gefitinib or any of the excipients of this product

          -  Less than 4 weeks since completion of prior chemotherapy or radiation therapy (except
             nitrosoureas or mitomycin-C which must have a wash out period of 6 weeks)

          -  Incomplete healing from previous oncologic or other major surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2005</study_first_submitted>
  <study_first_submitted_qc>August 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>April 22, 2009</last_update_submitted>
  <last_update_submitted_qc>April 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alison Armour, MD, IRESSA Medical Science Director</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

